In addition, the phosphoinositide-3-kinase catalytic subunit-α (PI3KCA)/AKT/mammalian target of rapamycin (mTOR) signaling pathway has also been investigated to identify platinum resistance mechanisms and to predict platinum effects [2–5]; however, the clinical relevance of this pathway in NSCLC has not yet been validated. This evidence concerns the gene MTOR and non-small cell lung carcinoma.